ProCE Banner Activity

Current Use of PARP Inhibitors in Prostate Cancer: Rationale and Key Monotherapy Data

Slideset Download
Download these slides from a live symposium for the latest evidence on PARP inhibitor monotherapy for the treatment of metastatic castration-resistant prostate cancer.

Released: February 22, 2022

Expiration: February 21, 2023

No longer available for credit.

Share

Faculty

Wassim Abida

Wassim Abida, MD, PhD

Director of Translational Research, Prostate Cancer
Associate Member
Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Wassim Abida, MD, PhD

Director of Translational Research, Prostate Cancer
Associate Member
Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Wassim Abida, MD, PhD, has disclosed that he has received consultant/advisor/speaker fees from AstraZeneca/MedImmune, Clovis Oncology, Daiichi Sankyo, Janssen, ORIC, and Roche and funds for research support paid to his institution from AstraZeneca, Clovis Oncology, Epizyme, ORIC, and Zenith Epigenetics.